INSIGHT. Looking back at pharmaceutical industry acquisition activity in 2024, a clear trend emerges: immunology and cancer dominated. These areas accounted for 70% of total transaction value, sending a strong signal about the industry’s growth potential.
According to Biopharma Dive, 2024 saw a total of 39 acquisitions valued at over 50 million USD, with a combined value of 46 billion USD. Deals in immunology and cancer exceeded 1.2 billion USD per transaction on average. Cancer immunotherapies have been a particularly prominent segment, where innovations in advanced biological methods such as cell and gene therapies, antibody-drug conjugates (ADC), and bispecific antibodies have driven some of the year’s largest transactions.
The trend becomes even clearer when looking at the year’s largest transactions. Novartis’ acquisition of MorphoSys, Johnson & Johnson’s purchase of Ambrx, and Roche’s acquisition of Poseida Therapeutics show how world-leading pharmaceutical companies are strategically strengthening their positions in these rapidly growing areas.
This opens up exciting opportunities for innovative biotech companies developing the next generation of treatments in these areas. Particularly promising is the increasing focus on new treatment methods that address significant unmet medical needs where effective alternatives are still lacking. The high transaction values and strong industry interest underscore the potential, making it an exciting space to watch in the coming years.
Receive news and invitations from Sciety
Join our newsletter to be the first to know about new investment opportunities and receive invitations to company presentations, seminars, and events.
Disclaimer: The information contained in our emails and communications is intended for informational purposes only and is not intended to constitute advice or recommendations on any investment. We do not guarantee the accuracy, completeness, timeliness, or suitability of any information provided. Please note that our communications are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. In particular, our communications are not intended for persons in the United States or Australia. We do not accept any liability for any loss or damage arising from the use of our communications, including but not limited to any investment decisions made based on the information provided. Furthermore, please note that any investment in private companies involves a high degree of risk and is not suitable for all investors. Before making any investments, you must read and accept our general terms and conditions for investments, which can be found at the following link: General Terms and Conditions for Investments.
